Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.

Abstract: Embodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. Aspects include methods and compositions for providing a passive immune response against the bacteria. In certain embodiments, the methods and compositions involve an antibody that binds Staphylococcal protein A (SpA).

Abstract: Antibodies and antigen binding fragments that bind to neublastin polypeptides are disclosed. Also disclosed are methods of using the antibodies and antigen binding fragments in assays for detecting the presence or amount of endogenous and/or exogenous neublastin in a sample and in methods of antagonizing neublastin bioactivity.

Abstract: Uses of the protein cereblon as a predictor of clinical sensitivity to cancer, inflammatory diseases, and patient response to drug treatment.

Abstract: The present invention provides antibodies that bind to the cat allergen, Fel d1, compositions comprising the antibodies, nucleic acids encoding the antibodies and methods of use of the antibodies. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Fel d1. The antibodies of the invention are useful for binding to the Fel d1 allergen in vivo, thus preventing binding of the Fel d1 allergen to pre-formed IgE on the surface of mast cells or basophils. In doing so, the antibodies act to prevent the release of histamine and other inflammatory mediators from mast cells and/or basophils, thus ameliorating the untoward response to the cat allergen in sensitized individuals. The antibodies of the invention may also be useful for diagnostic purposes to determine if a patient is allergic to the Fel d1 cat allergen.

Abstract: The present invention provides antibodies that bind to the cat allergen, Fel d1, compositions comprising the antibodies, nucleic acids encoding the antibodies and methods of use of the antibodies. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to Fel d1. The antibodies of the invention are useful for binding to the Fel d1 allergen in vivo, thus preventing binding of the Fel d1 allergen to pre-formed IgE on the surface of mast cells or basophils. In doing so, the antibodies act to prevent the release of histamine and other inflammatory mediators from mast cells and/or basophils, thus ameliorating the untoward response to the cat allergen in sensitized individuals. The antibodies of the invention may also be useful for diagnostic purposes to determine if a patient is allergic to the Fel d1 cat allergen.

Abstract: An Ang2 specific antibody, a method of inhibiting angiogenesis or a method of treating a disease related to the activation and/or overproduction of Ang2 using the antibody, and a composition for diagnosing a disease related to the activation and/or overproduction of Ang2 including the antibody.

Abstract: The present invention relates to isolated antibodies and antigen-binding fragments thereof which bind human BMP9 and compositions and methods of use thereof.

Abstract: The invention provides an isolated antibody or a fragment thereof, which is directed to the human chemokines CXCL1, CXCL7 and CXCL8, said antibody or fragment being capable of binding to the human chemokine CXCL1 with an equilibrium dissociation constant (KD) of at most 16 nM, to the human chemokine CXCL7 with an equilibrium dissociation constant (KD) of at most 5 nM and to the human chemokine CXCL8 with an equilibrium dissociation constant (KD) of at most 45 nM, as determined by surface plasmon resonance. The invention also provides some applications of said isolated antibody.

Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for ACTH. Embodiments of this invention relate to the binding fragments of antibodies described herein, comprising the sequences of the VH, VL and/or CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates anti-ACTH antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention further contemplates methods of making said anti-ACTH antibodies and binding fragments thereof.

Abstract: The invention provides anti-TIGIT (T-cell immunoreceptor with Ig and ITIM domains) antibodies and methods of using the same.

Abstract: The present invention provides a method for the selection of bispecific single chain antibodies comprising a first binding domain capable of binding to an epitope of CD3 and a second binding domain capable of binding to the extracellular do main cell surface antigens with a high molecular weight extracellular domain. Moreover, the invention provides bispecific single chain antibodies produced by the use of the method of the invention, nucleic acid molecules encoding these antibodies, vectors comprising such nucleic acid molecules and methods for the production of the antibodies. Furthermore, the invention provides pharmaceutical compositions comprising bispecific single chain antibodies of the invention, medical uses of the same and methods for the treatment of diseases comprising the administration of bispecific single chain antibodies of the invention.

Abstract: The present invention provides antibodies that bind to the class III variant of EGFR (EGFRvIII) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human EGFRvIII with high affinity. The antibodies of the invention may be fully human antibodies. The invention includes anti-EGFRvIII antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers.

Abstract: The present disclosure provides antibodies that bind to interleukin-3 receptor alpha chain and uses thereof.

Abstract: Herein is reported a method for reducing the aggregation of an immunoglobulin in solution comprising the steps of i) comparing the amino acid sequence of the fourth framework region of the heavy chain of an antibody with a reference or germline sequence and determining whether one or more threonine residues and/or serine residues have been replaced by a different amino acid residue, and ii) modifying the amino acid sequence of the immunoglobulin by reverting the exchanged threonine residues and/or serine residues back to threonine or serine of the reference or germline sequence and thereby reducing the aggregation of an immunoglobulin in solution.

Abstract: Provided are novel multispecific antibody constructs and multispecific antibody drug conjugates (ADCs), and methods of using such antibodies and ADCs to treat cancer. IgG-like bispecific antibodies have different binding specificities on each arm of the antibody. They are similar in structure to monospecific IgGs in that they contain two heavy chains with VH, CH1, CH2 and CH3 regions, and two light chains with VL and CL regions.

Abstract: A composition comprising a TLR2 antagonistic antibody or antigen binding fragment thereof for use in the treatment or prophylaxis of pancreatic cancer is provided. The antibody or antigen binding fragment may be provided for simultaneous, separate or sequential administration with a secondary chemotherapeutic agent such as gemcitabine, and optionally a tertiary chemotherapeutic agent such as abraxane for enhanced treatment. Also provided is a screening method for the identification of compounds for use in treatment or prevention of pancreatic cancer.

Abstract: The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.

Abstract: A novel humanized anti-IgE antibody is disclosed. The antibody is capable of binding to free IgE, membrane-bound IgE on B lymphocytes, IgE bound by CD23, but not to IgE bound by high-affinity IgE.Fc receptor on mast cells. The present invention relates to the treatment of IgE-mediated diseases, including allergic asthma, allergic rhinitis, atopic dermatitis, food allergy, chronic spontaneous (idiopathic) urticaria, chronic rhinosinusitis, systemic mastocytosis, cutaneous mastocytosis, allergic bronchopulmonary aspergillosis, recurrent idiopathic angioedema, and eosinophil-associated gastrointestinal disorder by administering the anti-IgE antibody of the present invention.

Abstract: The present invention provides methods for producing Fabs and bi-specific antibodies comprising designed residues in the interfaces of the heavy chain-light chain variable (VH/VL) domain and the heavy chain-light chain constant (CH1/CL] domain, Fabs and bi-specific antibodies produced according to said processes and host cells encoding the same.

Abstract: There is provided a process for the preparation of purified ?-(1,3)-D-glucans, comprising the steps of providing an aqueous ?-(1,3)-D-glucan initial solution having a pH of above 11.0, filtering the aqueous ?-(1,3)-D-glucan initial solution to obtain a ?-(1,3)-D-glucan containing filtrate, adjusting the pH of the ?-(1,3)-D-glucan containing filtrate with an acid to a pH of below 5.0 to obtain an acidic ?-(1,3)-D-glucan solution, and heating the acidic ?-(1,3)-D-glucan solution to a temperature in the range of 60 to 160° C.

Abstract: There is provided a process for the preparation of purified ?-(1,3)-D-glucans, comprising the steps of providing an aqueous ?-(1,3)-D-glucan initial solution having a pH of above 11.0, filtering the aqueous ?-(1,3)-D-glucan initial solution to obtain a ?-(1,3)-D-glucan containing filtrate, adjusting the pH of the ?-(1,3)-D-glucan containing filtrate with an acid to a pH of below 5.0 to obtain an acidic ?-(1,3)-D-glucan solution, and heating the acidic ?-(1,3)-D-glucan solution to a temperature in the range of 60 to 160°C.

Abstract: There is provided a process for the preparation of purified ?-(1,3)-D-glucans, comprising the steps of providing an aqueous ?-(1,3)-D-glucan initial solution having a pH of above 11.0, filtering the aqueous ?-(1,3)-D-glucan initial solution to obtain a ?-(1,3)-D-glucan containing filtrate, adjusting the pH of the ?-(1,3)-D-glucan containing filtrate with an acid to a pH of below 5.0 to obtain an acidic ?-(1,3)-D-glucan solution, and heating the acidic ?-(1,3)-D-glucan solution to a temperature in the range of 60 to 160° C.

Abstract: The present invention concerns a compound of formula (I): wherein: —n is an integer comprised between 1 and 7; —X1 is in particular a radical of formula —CH2—S—(CH2)k—S—; —A1 is in particular a linear or branched alkylene radical comprising from 2 to 30 carbon atoms, and —X2 is in particular an alkoxy group of formula ORa, wherein Ra is a linear or branched alkyl group comprising from 1 to 10 carbon atoms.

Abstract: A process for manufacturing a cross-linked hyaluronic acid (HA) containing a functionalizing group including the step of reacting HA with a mixture of: (i) a first cross-linking agent selected from the group of bifunctional epoxides and polyfunctional epoxides, and (ii) a functionalized agent of a functionalizing group coupled via a 1,2,3-triazole linkage to a second cross-linking agent selected from the group of bifunctional epoxides and polyfunctional epoxides, to obtain a cross-linked HA containing the functionalizing group. The process provides a cross-linked hyaluronic acid (HA) containing a functionalizing group. The process utilizes a functionalized agent of a functionalizing group coupled via a 1,2,3-triazole linkage to a cross-linking agent.

Abstract: The present invention relates to a modified elastomeric polymer obtained by reacting a living anionic elastomeric polymer and specific chain end modifying compound, wherein the living anionic elastomeric polymer comprises more than 70% and less than 99% by weight of butadiene units and more than 1% and less than 30% by weight of styrene units and has a vinyl bond content of from 2 to less than 10%, based on the polybutadiene fraction of the living anionic elastomeric polymer. The invention further relates to a method of preparing the modified elastomeric polymer and to an elastomeric polymer composition comprising the modified elastomeric polymer.

Abstract: A method for producing highly reactive olefin polymers wherein at least 50 mol. % of the polymer chains have terminal double bonds, from an isobutylene or a mixed C4 hydrocarbyl feedstock containing isobutylene. To achieve a viable process, water is added to the catalyst stream or the feedstock in the overall range of 0.05 mM to less than 5 mM per liter of feedstock.

Abstract: The present invention provides an aqueous dispersion of a low-molecular-weight polytetrafluoroethylene (PTFE), which contains an easily removable surfactant, and has a good dispersion stability. Specifically, the present invention provides an aqueous dispersion of a low-molecular-weight PTFE comprising tetrafluoroethylene (TFE) units, or TFE units and modifying monomer units which are copolymerizable with the TFE units, wherein the aqueous dispersion contains from 70 to 9,000 ppm, based on the aqueous dispersion, of a fluorine-containing compound of the formula (1) below: X—(CF2)m—Y??(1) where X is H or F; m is an integer from 3 to 5; and Y is —SO3M, —SO4M, —SO3R, —SO4R, —COOM, —PO3M2 or —PO4M2, M being H, NH4 or an alkali metal, and R being an alkyl group having 1 to 12 carbons, and the low-molecular-weight PTFE has an average primary particle size of from 100 to 350 nm.

Abstract: A slurry polymerization process for the preparation of polyethylene in a reactor cascade of two or more polymerization reactors including the steps of feeding to a polymerization reactor amounts of ethylene, of a Ziegler catalyst, of fresh aluminum alkyl and of a diluent; feeding the slurry product withdrawn from the polymerization reactor to a second polymerization reactor; and feeding additional amounts of ethylene and of diluent wherein the ethylene is first passed through an ethylene purification unit, which reduces at least the concentration of carbon monoxide, carbon dioxide, oxygen, acetylene and water contained in the ethylene, before it is fed to the two or more polymerization reactors of the reactor cascade.

Abstract: The present disclosure provides a process for the reduction of residual acidity of halogenated polymer. The process involves treating the halogenated polymer to a physical process such as rotary vacuum drying and then neutralizing the treated halogenated polymer with alkaline metal salt solutions. The process requires less quantity of an economic neutralizing agent/base during chemical treatment, thus improving process economy without prejudicing quality of the final halogenated polymer.

Abstract: This disclosure relates to a process for polymerization, and in particular to minimizing undesired polymerization reactions downstream of a polymerization reaction zone, for instance by use of a quenching agent that enables fast reaction rates with active polymerization catalyst in the polymerization effluent, so as to quench the catalyst quickly, thereby preventing uncontrolled polymerization reactions. A preferred quenching agent is methanol. Also provided are means for treating polymer recycle streams containing oxygenates, which may result from the use of such quench agents, particularly in polymerization processes including polyene (e.g., diene) monomers.

Abstract: Provided is a styrene resin composition including ?-methyl styrene, acrylonitrile and t-butyl methacrylate, and having an improved conversion rate while maintaining excellent mechanical and chemical properties, a styrene resin composition including the same, and a styrene resin molded product manufactured therefrom. Accordingly, the heat-resistant styrene copolymer is effective in improving a conversion rate without deformation and mechanical and chemical property decline of the material itself, and as a result, commercialization may be readily accomplished due to enhanced productivity. In addition, the styrene resin molded product manufactured from the styrene resin composition according to the present invention includes the heat-resistant styrene copolymer as a matrix copolymer, and therefore, has excellent impact strength, tensile strength, tensile elongation and flowability while having high heat resistance.

Abstract: The present invention relates to vinyl-based thermoplastic resin composition having excellent thermal stability, which comprises a metal complex agent, and a first vinyl-based monomer and a second vinyl-based monomer having different iron ion concentration from each other, a method for manufacturing thereof, and vinyl-based thermoplastic resin manufactured therefrom. The accompanying vinyl-based thermoplastic resin composition can enhance thermal stability, and the vinyl-based thermoplastic resin manufactured from the composition may have excellent thermal stability. Thus, it can be easily applied to industries requiring thereof, in particular, industries of vinyl-based thermoplastic resin and its mold processed goods.

Abstract: The invention pertains to a tetrafluoroethylene (TFE) copolymer comprising recurring units derived from at least one perfluoroalkyl(oxy)vinylether of formula CF2?CF—O—Rf, wherein Rf is a C1-C6 perfluoroalkyl radical possibly comprising one or more ethereal oxygen atoms [monomer (F)], in an amount of 0.005 to 0.025% moles, with respect to the total moles of the copolymer, wherein a particular relation between monomer content and amorphous index is satisfied, and to a process for its manufacture by emulsion polymerization in the presence of certain cyclic surfactants.

Abstract: Provided is a method of forming fine patterns capable of minimizing LER and LWR to form high quality nanopatterns, by using a block copolymer having excellent etching selectivity.

Abstract: There are provided a photoreactive copolymer and an alignment layer comprising the same, and more particularly, to a photoreactive copolymer including a copolymer of two different kinds of monomers, and an alignment layer comprising the same. The photoreactive copolymer according to the present invention may have excellent liquid crystal alignment property and alignment speed, easily change an alignment direction depending on a polarization direction, and have excellent solubility to an organic solvent, such that the photoreactive copolymer may be used in various fields such as a liquid crystal device, and the like.

Abstract: A film-forming composition containing a polymer obtained by polymerizing (A) 5 to 80 mass % of a silicone resin having an R3SiO1/2 unit, an R2R?SiO1/2 unit, and an SiO2 unit, where R may be the same or different and represents a monovalent hydrocarbon group having 1 to 6 carbon atoms, and R? represents a —C3H6SH group, wherein a total amount of the R3SiO1/2 unit, R2R?SiO1/2 unit, and SiO2 unit is 80 mol % or more with respect to all structural units, and a mole ratio expressed by (sum of R3SiO1/2 unit and R2R?SiO1/2 unit)/(SiO2 unit) ranges from 0.5 to 1.5 and (B) 20 to 95 mass % of one or more radically polymerizable compounds, wherein component (B) includes (B-1) one or more radically polymerizable monomers having no SiO unit in a structure thereof. This composition is capable of forming a transparent film that is excellent in adhesiveness without exhibiting stickiness and secondary adhesion.

Abstract: A novolac-type phenolic hydroxyl group-containing resin with formula (1) as a structural site repeating unit, R1 represents one of a hydrogen atom, an alkyl group, and an aryl group, and X represents a structural site (?) represented by formula (2), R2 and R3 each represent one of a hydrogen atom, an alkyl group, an aryl group, and an aralkyl group; n and m are each an integer of 1 to 3; when n or m is 2 or 3, a plurality of each of R2 and R3 present in a molecule may be the same or different; and Ar represents one of a phenyl group, a naphthyl group, an anthryl group, and a structural site in which one or a plurality of hydrogen atoms in an aromatic nucleus of any one of these groups is substituted by one of an alkyl group, an aryl group, and an aralkyl group).

Abstract: The present invention provides a photosensitive composition having excellent heat resistance, low absorbance at the exposure light at wavelengths of g-line, h-line, and i-line, and satisfactory sensitivity even when the thickness of a resist film is increased, and also provides a resist material, a coating film thereof, a novolac phenol resin suitable for these applications, and a method for producing the phenol resin.

Abstract: Polyurethane foams which are highly flame resistant are described, as well as the production of such polyurethane foams by the reaction between a natural polyol, such as sucrose or a blend of mono- or disaccharides in place of the standard hydrocarbon-based polyol component, a polyisocyanate and water in the presence of a suitable polyurethane forming catalyst and a non-halogenated flame retardant, and optionally one or more components such as surfactants and/or emulsifiers. The resultant polyurethane foam has a bio-based solid content ranging from about 17% to 30%, may be formulated in a variety of foam densities for a variety of applications, and exhibits a high degree of fire and burn resistance, as exhibited by the flame spread index, flash over resistance determination, and the smoke spread values.

Abstract: Disclosed are high strength polyurethane foam compositions and methods of making them. In one aspect, the inventive polyurethane foams include strength enhancing additives comprising one or more polycarbonate polyols derived from the copolymerization of CO2 and one or more epoxides. In one aspect, the inventive methods include the step of substituting a portion of the polyether polyol in the B-side of a foam formulation with one or more polycarbonate polyols derived from the copolymerization of CO2 and one or more epoxides.

Abstract: It is an object of the invention to provide a block polyisocyanate compound with excellent storage stability. The block polyisocyanate compound of the invention has the following construction. A block polyisocyanate compound having at least one block isocyanate group selected from the group consisting of a block isocyanate group represented by formula (I), block isocyanate group represented by formula (II) and block isocyanate group represented by formula (III), and a hydrophilic group.

Abstract: Provided are a curable resin composition capable of providing excellent heat resistance and toughness for a cured product, in which these physical properties are less deteriorated even in a case of being exposed to humidity and heat conditions, and a cured product, a fiber reinforced composite material, and a molded article thereof. The curable resin composition includes an epoxy resin and a curing agent, in which the epoxy resin is an epoxy resin obtained by the polyglycidyl-etherification of a phenol novolac resin. The phenol novolac resin contains bisphenol F having different binding sites, and in the bisphenol F components, the content of the [o, p?] conjugate is in a range of 30% to 45% relative to the total of the [o, p?] conjugate+the [o, o?] conjugate+the [p, p?] conjugate in terms of the area ratio according to a liquid chromatography measurement.

Abstract: The present invention relates to a compound containing phosphonium ion of a chemical formula 1, an epoxy resin composition containing the same, and a device manufactured by using the same.

Abstract: Optical materials including polymerizable compositions and oligomeric and polymeric material formed therefrom. The oligomer or polymer material include structural repeat units. The optical material has low or substantially no absorbance of wavelengths in at least one of the spectral regions of interest. Optical components include adhesives, waveguides, spherical or non-spherical optical lenses, architectural articles, automotive components, laminated structures and composites.

Abstract: A polymer and a method for its preparation are provided. The polymer comprises poly(lactide), poly(lactide/glycolide) or poly(lactic acid/glycolic acid) segments bonded by ester linkages to both ends of an alkanediol core unit. The polymer is for use in a controlled release formulation for a medicament, preferably leuprolide acetate. The controlled release formulation is administered to a patient as a subcutaneous depot of a flowable composition comprising the polymer, a biocompatible solvent, and the medicament. Controlled release formulations comprising the polymer release leuprolide for treatment of prostate cancer patients over periods of 3-6 months.

Abstract: A biodegradable polyester is consisting of a poly(terephthalate-di-(?-caprolactone) segment, a poly(terephthalate-butylene-terephthalate) segment, a poly(terephthalate-butylene-?-caprolactone) segment, a poly(?-caprolactone-butylene-?-caprolactone) segment, and a poly(tri(?-caprolactone) segment. The above five segments are obtained by polycondensation reaction of terephthalic acid, 1,4-butanediol and ?-caprolactone under the presence of a catalyst, with a polycondensation temperature of 255° C. to 270° C. and a polycondensation time of 2 hours to 4 hours. Furthermore, based on 1 mole of terephthalic acid, a molar ratio of 1,4-butanediol to terephthalic acid is in the range of 1.1 to 1.4, and a molar ratio of ?-caprolactone to terephthalic acid is in the range of 0.5 to 1.6. The biodegradable polyester can have a melting point (Tm) of 90° C. to 170° C.

Abstract: The present invention relates to the use of monomers bearing associative groups in order to manufacture a supramolecular polycondensate, to certain of these monomers, to a process for manufacturing a supramolecular polycondensate, to the polycondensate obtained, and also to an article or a composition incorporating same. The associative groups may be, for example, imidazolidone, urea or triazole groups.

Abstract: The present disclosure relates to an organic zinc catalyst suppressing agglomeration among catalyst particles during a manufacturing method to have more uniform and finer particle size, thereby showing a more improved activity in a polymerization process for manufacturing a polyalkylene carbonate resin, a manufacturing method thereof, and a manufacturing method of a polyalkylene carbonate resin using the same, wherein the organic zinc catalyst is a zinc dicarboxylate-based organic zinc catalyst used for a reaction in which a polyalkylene carbonate resin is manufactured from carbon dioxide and epoxide and includes a monocarboxylic acid-derived moiety having a C3-C15 aliphatic hydrocarbon group (provided that at least one oxygen or carbonyl group is included or not included in the aliphatic hydrocarbon group) that is bonded to an end of at least one side of the zinc dicarboxylate-based organic zinc catalyst.

Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. Compositions herein are useful for drug-delivery applications.